This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $990,771 to Binary Genomics, Inc. to develop a novel circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapy treatments. The project aims to build clinical data to support the utility of this epigenetic-based ctDNA assay for tracking patient response to immunotherapies, without requiring customized tumor mutation profiling. This technology seeks to address limitations of current ctDNA approaches that rely on detecting common somatic mutations. The award period runs from September 2024 through August 2026, with the goal of advancing the research-mode assay to rigorous clinical-grade testing standards for use in clinical practice.
Generated 2/25/25, 4:38 AM